{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:39Z","timestamp":1740167739283,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010628","name":"Universidad de La Sabana","doi-asserted-by":"crossref","award":["MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023"],"award-info":[{"award-number":["MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023","MEDMSc-77-2023"]}],"id":[{"id":"10.13039\/501100010628","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Venous thromboembolic disease (VTE) is characterized by obstruction of venous blood flow by a thrombus. Survival data, frequency of disease recurrence, and bleeding rate in patients on anticoagulant therapy with warfarin compared to rivaroxaban in the Latin American population are limited in VTE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study with propensity score matching analysis was conducted in patients with pulmonary embolism and\/or deep vein thrombosis anticoagulated with warfarin or rivaroxaban treated. Survival analysis was performed using a Kaplan-Meier curve for each of the intervention groups, and it was compared using a Log Rank test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 2193 potentially eligible patients with a suspected diagnosis of VTE, 505 patients entered the analysis; of these, 285 subjects were managed with warfarin and 220 anticoagulated with rivaroxaban. Major bleeding at 12 months occurred in 2.7% (6\/220) of patients treated with Rivaroxaban, compared to 10.2% (29\/285) in the Warfarin group in the unmatched population (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). In the matched population, bleeding at 12 months occurred in 2.9% (6\/209) of patients on Rivaroxaban and in 11.0% (23\/209) of patients on Warfarin (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). The survival rates at 6 months were 97.1% for Rivaroxaban and 97.6% for Warfarin (<jats:italic>p<\/jats:italic>\u2009=\u20090.76). At 12 months, the survival rates were 94.7% for Rivaroxaban and 95.7% for Warfarin (<jats:italic>p<\/jats:italic>\u2009=\u20090.61).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the treatment of VTE, there is no differences on 6 and 12-month survival or a reduction in the occurrence of new thromboembolic events when comparing rivaroxaban to warfarin. However, a lower risk of major bleeding is observed at 12 months with Rivaroxaban.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-023-00712-8","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T13:02:24Z","timestamp":1702472544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin \u2013 propensity score matching study"],"prefix":"10.1186","volume":"24","author":[{"given":"Estefan","family":"Ramos-Isaza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Tuta-Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-9779","authenticated-orcid":false,"given":"Alirio","family":"Bastidas-Goyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Diaz-Quijano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Aponte-Murcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Espitia-Angel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pinto-Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Rinc\u00f3n-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"S\u00e1nchez-Cuellar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"P\u00e9rez-Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"Giraldo-Cadavid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"issue":"3","key":"712_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10238-022-00829-w","volume":"23","author":"S Navarrete","year":"2023","unstructured":"Navarrete S, Solar C, Tapia R, Pereira J, Fuentes E, Palomo I. Pathophysiology of deep vein thrombosis. Clin Exp Med. 2023;23(3):645\u201354.","journal-title":"Clin Exp Med"},{"issue":"8","key":"712_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083853","volume":"22","author":"A Brill","year":"2021","unstructured":"Brill A. Multiple facets of venous thrombosis. Int J Mol Sci. 2021;22(8): 3853.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"712_CR3","doi-asserted-by":"publisher","first-page":"ITC129","DOI":"10.7326\/AITC202209200","volume":"175","author":"L Duffett","year":"2022","unstructured":"Duffett L. Deep venous thrombosis. Ann Intern Med. 2022;175(9):ITC129-144.","journal-title":"Ann Intern Med"},{"issue":"4","key":"712_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.emc.2017.06.003","volume":"35","author":"M Olaf","year":"2017","unstructured":"Olaf M, Cooney R. Deep venous thrombosis. Emerg Med Clin. 2017;35(4):743\u201370.","journal-title":"Emerg Med Clin"},{"key":"712_CR5","doi-asserted-by":"publisher","first-page":"107602962311607","DOI":"10.1177\/10760296231160753","volume":"29","author":"Z Wang","year":"2023","unstructured":"Wang Z, Yang Y, He X, Jiang X, Gao X, Liu P, et al. Incidence and clinical features of venous thromboembolism in inpatients with Mental Illness. Clin Appl Thromb Hemost. 2023;29:10760296231160752.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2 Suppl","key":"712_CR6","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S-496.","journal-title":"Chest"},{"issue":"8","key":"712_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1177\/0268355516678729","volume":"32","author":"M Kafeza","year":"2017","unstructured":"Kafeza M, Shalhoub J, Salooja N, Bingham L, Spagou K, Davies AH. A systematic review of clinical prediction scores for deep vein thrombosis. Phlebology. 2017;32(8):516\u201331.","journal-title":"Phlebology"},{"issue":"4","key":"712_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.36660\/abc.20220213","volume":"118","author":"ACL Albricker","year":"2022","unstructured":"Albricker ACL, Freire CMV, Santos SND, Alcantara ML, Saleh MH, Cantisano AL, et al. Joint Guideline on venous thromboembolism \u2013 2022. Arq Bras Cardiol. 2022;118(4):797\u2013857 (English, Portuguese).","journal-title":"Arq Bras Cardiol"},{"issue":"10063","key":"712_CR9","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","volume":"388","author":"M Di Nisio","year":"2016","unstructured":"Di Nisio M, van Es N, B\u00fcller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060\u201373.","journal-title":"Lancet"},{"issue":"9","key":"712_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17474086.2018.1502082","volume":"11","author":"GJAM Boon","year":"2018","unstructured":"Boon GJAM, Van Dam LF, Klok FA, Huisman MV. Management and treatment of deep vein thrombosis in special populations. Expert Rev Hematol. 2018;11(9):685\u201395.","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"712_CR11","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1111\/jth.15048","volume":"18","author":"L Franco","year":"2020","unstructured":"Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R, et al. Definition of major bleeding: prognostic classification. J Thromb Haemost. 2020;18(11):2852\u201360.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"712_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"712_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"712_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/9781118548387","volume-title":"Applied Logistic Regression","author":"DW Hosmer","year":"2013","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX. Special topics. In: Hosmer DW, Lemeshow S, Sturdivant RX, editors. Applied Logistic Regression. 3rd ed. New York, NY: John Wiley & Sons, Inc; 2013. p. 401\u20138.","edition":"3"},{"issue":"3","key":"712_CR15","first-page":"111","volume":"33","author":"RJ Dennis","year":"2008","unstructured":"Dennis RJ, Rojas MX, Molina \u00c1, Roa J, Granados M, Londo\u00f1o A, et al. Curso cl\u00ednico Y supervivencia en embolia pulmonar: resultados del registro multic\u00e9ntrico colombiano (EMEPCO). Acta Med Col. 2008;33(3):111\u20136.","journal-title":"Acta Med Col"},{"key":"712_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.thromres.2018.05.031","volume":"168","author":"CI Coleman","year":"2018","unstructured":"Coleman CI, Peacock WF, Bunz TJ, Beyer-Westendorf J. Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: a propensity-score weighted administrative claims cohort study. Thromb Res. 2018;168:31\u20136.","journal-title":"Thromb Res"},{"issue":"5","key":"712_CR17","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/S2352-3026(17)30054-6","volume":"4","author":"TB Larsen","year":"2017","unstructured":"Larsen TB, Skj\u00f8th F, Kj\u00e6ldgaard JN, Lip GYH, Nielsen PB, S\u00f8gaard M. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Lancet Haematol. 2017;4(5):e237-244.","journal-title":"Lancet Haematol"},{"issue":"3","key":"712_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T van der Hulle","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320\u20138.","journal-title":"J Thromb Haemost"},{"issue":"26","key":"712_CR19","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","journal-title":"N Engl J Med"},{"issue":"14","key":"712_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"B\u00fcller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic Pulmonary Embolism. N Engl J Med. 2012;366(14):1287\u201397.","journal-title":"N Engl J Med"},{"issue":"3","key":"712_CR21","doi-asserted-by":"publisher","first-page":"e234086","DOI":"10.1001\/jamanetworkopen.2023.4086","volume":"6","author":"KJ Lin","year":"2023","unstructured":"Lin KJ, Singer DE, Bykov K, Bessette LG, Mastrorilli JM, Cervone A, et al. Comparative effectiveness and safety of oral anticoagulants by dementia status in older patients with atrial fibrillation. JAMA Netw Open. 2023;6(3):e234086.","journal-title":"JAMA Netw Open"},{"key":"712_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1265331","volume":"10","author":"D Wang","year":"2023","unstructured":"Wang D, Xu X, Han X, Xie J, Zhou H, Peng W, et al. Clinical benefits of oral anticoagulants in atrial fibrillation patients with Dementia: a systematic review and meta-analysis. Front Cardiovasc Med. 2023;10: 1265331.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"712_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-240059","volume":"14","author":"KMF Porter","year":"2021","unstructured":"Porter KMF, Hargreaves IP, De Souza S, Goddard R. Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of Dementia (BPSD). BMJ Case Rep. 2021;14(3): e240059.","journal-title":"BMJ Case Rep"},{"issue":"11","key":"712_CR24","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1161\/STROKEAHA.120.033338","volume":"52","author":"SR Lee","year":"2021","unstructured":"Lee SR, Choi EK, Park SH, Jung JH, Han KD, Oh S, et al. Comparing warfarin and 4 direct oral anticoagulants for the risk of dementia in patients with atrial fibrillation. Stroke. 2021;52(11):3459\u201368.","journal-title":"Stroke"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00712-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T13:05:22Z","timestamp":1702472722000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00712-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00712-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"type":"electronic","value":"2050-6511"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the current Helsinki Declaration, as well as local, regional, and international regulations pertaining to clinical research, including Colombian Law on Biomedical Research. Ethical approval was obtained from the Medical Ethics Committee of the Cl\u00ednica Universidad de La Sabana (approval number 20230606). Prior to participating in the study, all participants provided written informed consent, and the confidentiality of their data was strictly maintained throughout the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}